Tania C Sorrell

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/2136101/tania-c-sorrell-publications-by-year.pdf
Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

245 papers	15,819 citations	56 h-index	120 g-index
263 ext. papers	18,347 ext. citations	6.3 avg, IF	6.09 L-index

#	Paper	IF	Citations
245	MSG07: An International Cohort Study Comparing Epidemiology and Outcomes of Patients With Cryptococcus neoformans or Cryptococcus gattii Infections. *Clinical Infectious Diseases*, **2021**, 73, 1133-1141	11.6	5
244	Koala cathelicidin PhciCath5 has antimicrobial activity, including against Chlamydia pecorum. *PLoS ONE*, **2021**, 16, e0249658	3.7	1
243	Infection control professionalsSand infectious diseases physiciansSknowledge, preparedness, and experiences of managing COVID-19 in Australian healthcare settings. *Infection, Disease and Health*, **2021**, 26, 249-257	4.6	2
242	COVID-19 in Australia: our national response to the first cases of SARS-CoV-2 infection during the early biocontainment phase. *Internal Medicine Journal*, **2021**, 51, 42-51	1.6	2
241	Risk factors for candidaemia: A prospective multi-centre case-control study. *Mycoses*, **2021**, 64, 257-263	5.2	5
240	Trehalose as quantitative biomarker for in vivo diagnosis and treatment follow-up in cryptococcomas. *Translational Research*, **2021**, 230, 111-122	11	3
239	Azole-resistant Aspergillus fumigatus is highly prevalent in the environment of Vietnam, with marked variability by land use type. *Environmental Microbiology*, **2021**,	5.2	2
238	Consensus guidelines for the diagnosis and management of cryptococcosis and rare yeast infections in the haematology/oncology setting, 2021.. *Internal Medicine Journal*, **2021**, 51 Suppl 7, 118-142	1.6	4
237	The use of taxon-specific reference databases compromises metagenomic classification. *BMC Genomics*, **2020**, 21, 184	4.5	12
236	CCMetagen: comprehensive and accurate identification of eukaryotes and prokaryotes in metagenomic data. *Genome Biology*, **2020**, 21, 103	18.3	35
235	Inferring evolutionary pathways and directed genotype networks of foodborne pathogens. *PLoS Computational Biology*, **2020**, 16, e1008401	5	1
234	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. *Clinical Infectious Diseases*, **2020**, 71, 1367-1376	11.6	607
233	Long-read sequencing based clinical metagenomics for the detection and confirmation of Pneumocystis jirovecii directly from clinical specimens: A paradigm shift in mycological diagnostics. *Medical Mycology*, **2020**, 58, 650-660	3.9	18
232	Drug-Resistant Is Highly Prevalent in the Environment of Vietnam: A New Challenge for the Management of Aspergillosis?. *Journal of Fungi (Basel, Switzerland)*, **2020**, 6,	5.6	3
231	Monitoring Glycolysis and Respiration Highlights Metabolic Inflexibility of. *Pathogens*, **2020**, 9,	4.5	5
230	SARS-CoV-2 infection and COVID-19: The lived experience and perceptions of patients in isolation and care in an Australian healthcare setting. *American Journal of Infection Control*, **2020**, 48, 1445-1450	3.8	33
229	IP-SPX Domain Interaction Controls Fungal Virulence by Stabilizing Phosphate Signaling Machinery. *MBio*, **2020**, 11,	7.8	7

228	An emergent clade of SARS-CoV-2 linked to returned travellers from Iran. *Virus Evolution*, **2020**, 6, veaa027	3.7	93
227	Inferring evolutionary pathways and directed genotype networks of foodborne pathogens **2020**, 16, e1008401		
226	Inferring evolutionary pathways and directed genotype networks of foodborne pathogens **2020**, 16, e1008401		
225	Inferring evolutionary pathways and directed genotype networks of foodborne pathogens **2020**, 16, e1008401		
224	Inferring evolutionary pathways and directed genotype networks of foodborne pathogens **2020**, 16, e1008401		
223	Inferring evolutionary pathways and directed genotype networks of foodborne pathogens **2020**, 16, e1008401		
222	Inferring evolutionary pathways and directed genotype networks of foodborne pathogens **2020**, 16, e1008401		
221	Dual DNA Barcoding for the Molecular Identification of the Agents of Invasive Fungal Infections. *Frontiers in Microbiology*, **2019**, 10, 1647	5.7	24
220	Improving emergency preparedness and response in the Asia-Pacific. *BMJ Global Health*, **2019**, 4, e001276	6.6	7
219	Network properties of salmonella epidemics. *Scientific Reports*, **2019**, 9, 6159	4.9	6
218	Meta-transcriptomics reveals a diverse antibiotic resistance gene pool in avian microbiomes. *BMC Biology*, **2019**, 17, 31	7.3	40
217	Fungal Kinases With a Sweet Tooth: Pleiotropic Roles of Their Phosphorylated Inositol Sugar Products in the Pathogenicity of Present Novel Drug Targeting Opportunities. *Frontiers in Cellular and Infection Microbiology*, **2019**, 9, 248	5.9	6
216	Metatranscriptomics as a tool to identify fungal species and subspecies in mixed communities - a proof of concept under laboratory conditions. *IMA Fungus*, **2019**, 10, 12	6.8	12
215	Central Nervous System Cryptococcal Infections in Non-HIV Infected Patients. *Journal of Fungi (Basel, Switzerland)*, **2019**, 5,	5.6	37
214	Database establishment for the secondary fungal DNA barcode (). *Genome*, **2019**, 62, 160-169	2.4	17
213	In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi. *Medical Mycology*, **2018**, 56, 1050-1054	3.9	32
212	Opportunities and challenges to improving antibiotic prescribing practices through a One Health approach: results of a comparative survey of doctors, dentists and veterinarians in Australia. *BMJ Open*, **2018**, 8, e020439	3	20
211	Pseudomonas aeruginosa Inhibits the Growth of Scedosporium and Lomentospora In Vitro. *Mycopathologia*, **2018**, 183, 251-261	2.9	18

210	The Early Innate Immune Response to, and Phagocyte-Dependent Entry of, Cryptococcus neoformans Map to the Perivascular Space of Cortical Post-Capillary Venules in Neurocryptococcosis. *American Journal of Pathology*, **2018**, 188, 1653-1665	5.8	21
209	Responding to the emergence of antifungal drug resistance: perspectives from the bench and the bedside. *Future Microbiology*, **2018**, 13, 1175-1191	2.9	66
208	Watersheds in planetary health research and action. *Lancet Planetary Health, The*, **2018**, 2, e510-e511	9.8	6
207	Whole Genome Sequencing of Australian Isolates Reveals Genetic Diversity and Novel Sequence Types. *Frontiers in Microbiology*, **2018**, 9, 2946	5.7	15
206	Synthesis and Evaluation of a Series of Bis(pentylpyridinium) Compounds as Antifungal Agents. *ChemMedChem*, **2018**, 13, 1421-1436	3.7	9
205	Surveillance for azole resistance in clinical and environmental isolates of Aspergillus fumigatus in Australia and cyp51A homology modelling of azole-resistant isolates. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 2347-2351	5.1	20
204	The Case for Adopting the "Species Complex" Nomenclature for the Etiologic Agents of Cryptococcosis. *MSphere*, **2017**, 2,	5	185
203	Pho4 Is Essential for Dissemination of to the Host Brain by Promoting Phosphate Uptake and Growth at Alkaline pH. *MSphere*, **2017**, 2,	5	23
202	A planetary health approach to emerging infections in Australia. *Lancet, The*, **2017**, 389, 1293	40	3
201	Identification of genetic markers of resistance to echinocandins, azoles and 5-fluorocytosine in Candida glabrata by next-generation sequencing: a feasibility study. *Clinical Microbiology and Infection*, **2017**, 23, 676.e7-676.e10	9.5	18
200	IP kinase Arg1 regulates cell wall homeostasis and surface architecture to promote Cryptococcus neoformans infection in a mouse model. *Virulence*, **2017**, 8, 1833-1848	4.7	6
199	Is Australia prepared for the next pandemic?. *Medical Journal of Australia*, **2017**, 206, 284-286	4	1
198	Changing epidemiology of candidaemia in Australia. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 1103-1108	5.1	56
197	Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer. *Lancet Infectious Diseases, The*, **2017**, 17, e344-e356	25.5	99
196	Nuclear Magnetic Resonance Spectroscopy-Based Identification of Yeast. *Methods in Molecular Biology*, **2017**, 1508, 289-304	1.4	3
195	Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance. *Journal of Visualized Experiments*, **2017**,	1.6	15
194	Delivering on Antimicrobial Resistance Agenda Not Possible without Improving Fungal Diagnostic Capabilities. *Emerging Infectious Diseases*, **2017**, 23, 177-183	10.2	51
193	Influenza A Virus as a Predisposing Factor for Cryptococcosis. *Frontiers in Cellular and Infection Microbiology*, **2017**, 7, 419	5.9	16

192	Marsupial and monotreme cathelicidins display antimicrobial activity, including against methicillin-resistant Staphylococcus aureus. *Microbiology (United Kingdom)*, **2017**, 163, 1457-1465	2.9	8
191	Developing research priorities for Australia's response to infectious disease emergencies. *Communicable Diseases Intelligence*, **2017**, 41, E1-E3		
190	Cryptococcal transmigration across a model brain blood-barrier: evidence of the Trojan horse mechanism and differences between Cryptococcus neoformans var. grubii strain H99 and Cryptococcus gattii strain R265. *Microbes and Infection*, **2016**, 18, 57-67	9.3	62
189	Antifungal susceptibilities of non-Aspergillus filamentous fungi causing invasive infection in Australia: support for current antifungal guideline recommendations. *International Journal of Antimicrobial Agents*, **2016**, 48, 453-8	14.3	22
188	Cathelicidins in the Tasmanian devil (Sarcophilus harrisii). *Scientific Reports*, **2016**, 6, 35019	4.9	17
187	Stimulation with lysates of Aspergillus terreus, Candida krusei and Rhizopus oryzae maximizes cross-reactivity of anti-fungal T cells. *Cytotherapy*, **2016**, 18, 65-79	4.8	13
186	Mucormycosis in Australia: contemporary epidemiology and outcomes. *Clinical Microbiology and Infection*, **2016**, 22, 775-781	9.5	53
185	MLST and Whole-Genome-Based Population Analysis of Cryptococcus gattii VGIII Links Clinical, Veterinary and Environmental Strains, and Reveals Divergent Serotype Specific Sub-populations and Distant Ancestors. *PLoS Neglected Tropical Diseases*, **2016**, 10, e0004861	4.8	33
184	Identification and Characterization of VNI/VNII and Novel VNII/VNIV Hybrids and Impact of Hybridization on Virulence and Antifungal Susceptibility Within the C. neoformans/C. gattii Species Complex. *PLoS ONE*, **2016**, 11, e0163955	3.7	11
183	Future directions for public health research in emerging infectious diseases. *Public Health Research and Practice*, **2016**, 26,	5.1	9
182	Inositol Polyphosphate Kinases, Fungal Virulence and Drug Discovery. *Journal of Fungi (Basel, Switzerland)*, **2016**, 2,	5.6	8
181	Identification of a major IP5 kinase in Cryptococcus neoformans confirms that PP-IP5/IP7, not IP6, is essential for virulence. *Scientific Reports*, **2016**, 6, 23927	4.9	23
180	Problematic Dichotomization of Risk for Intensive Care Unit (ICU)-Acquired Invasive Candidiasis: Results Using a Risk-Predictive Model to Categorize 3 Levels of Risk From a Multicenter Prospective Cohort of Australian ICU Patients. *Clinical Infectious Diseases*, **2016**, 63, 1463-1469	11.6	29
179	Candida colonization as a risk marker for invasive candidiasis in mixed medical-surgical intensive care units: development and evaluation of a simple, standard protocol. *Journal of Clinical Microbiology*, **2015**, 53, 1324-30	9.7	32
178	International Society of Human and Animal Mycology (ISHAM)-ITS reference DNA barcoding database--the quality controlled standard tool for routine identification of human and animal pathogenic fungi. *Medical Mycology*, **2015**, 53, 313-37	3.9	195
177	Molecular diagnostic methods for invasive fungal disease: the horizon draws nearer?. *Pathology*, **2015**, 47, 257-69	1.6	36
176	Fungal Inositol Pyrophosphate IP7 Is Crucial for Metabolic Adaptation to the Host Environment and Pathogenicity. *MBio*, **2015**, 6, e00531-15	7.8	39
175	Pulmonary Cryptococcosis. *Seminars in Respiratory and Critical Care Medicine*, **2015**, 36, 681-91	3.9	40

174	Medical and veterinary mycology. *Microbiology Australia*, **2015**, 36, 42	0.8	
173	Modern technology and infectious diseases activity data: how can we use this for service planning?. *Internal Medicine Journal*, **2015**, 45, 688	1.6	
172	Rapid microscopy and use of vital dyes: potential to determine viability of Cryptococcus neoformans in the clinical laboratory. *PLoS ONE*, **2015**, 10, e0117186	3.7	14
171	Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality. *Clinical Microbiology and Infection*, **2015**, 21, 490.e1-10	9.5	97
170	Nocardia Species **2015**, 2853-2863.e2		6
169	Anti-granulocyte-macrophage colony-stimulating factor autoantibodies are a risk factor for central nervous system infection by Cryptococcus gattii in otherwise immunocompetent patients. *MBio*, **2014**, 5, e00912-14	7.8	139
168	Cryptococcus gattii infections. *Clinical Microbiology Reviews*, **2014**, 27, 980-1024	34	240
167	The Genus Scedosporium and Pseudallescheria: Current Challenges in Laboratory Diagnosis. *Current Clinical Microbiology Reports*, **2014**, 1, 27-36	3.1	6
166	Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre YeastOne for Candida albicans: a prospective observational cohort study. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 2210-4	5.1	21
165	Functional disruption of yeast metacaspase, Mca1, leads to miltefosine resistance and inability to mediate miltefosine-induced apoptotic effects. *Fungal Genetics and Biology*, **2014**, 67, 71-81	3.9	11
164	Cryptococcus neoformans: Latency and Disease **2014**, 429-439		8
163	Vulnerability, hysteria and fear - conquering Ebola virus. *Medical Journal of Australia*, **2014**, 201, 320-1	4	5
162	Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014. *Internal Medicine Journal*, **2014**, 44, 1315-32	1.6	50
161	Cryptococcus gattii in North American Pacific Northwest: whole-population genome analysis provides insights into species evolution and dispersal. *MBio*, **2014**, 5, e01464-14	7.8	108
160	Identification of Aph1, a phosphate-regulated, secreted, and vacuolar acid phosphatase in Cryptococcus neoformans. *MBio*, **2014**, 5, e01649-14	7.8	23
159	Clinical features of endemic community-acquired psittacosis. *New Microbes and New Infections*, **2014**, 2, 7-12	4.1	33
158	Detection of multiple fungal species in blood samples by real-time PCR: an interpretative challenge. *Journal of Clinical Microbiology*, **2014**, 52, 3515-6	9.7	2
157	Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. *Lancet Infectious Diseases, The*, **2013**, 13, 519-28	25.5	180

156	Functional characterization of the hexose transporter Hxt13p: an efflux pump that mediates resistance to miltefosine in yeast. *Fungal Genetics and Biology*, **2013**, 61, 23-32	3.9	8
155	Multiplex-tandem PCR for fungal diagnostics. *Methods in Molecular Biology*, **2013**, 968, 195-201	1.4	2
154	Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 745-50	5.9	24
153	Human rhinovirus C in adult haematopoietic stem cell transplant recipients with respiratory illness. *Journal of Clinical Virology*, **2013**, 56, 255-9	14.5	13
152	Phospholipase C of Cryptococcus neoformans regulates homeostasis and virulence by providing inositol trisphosphate as a substrate for Arg1 kinase. *Infection and Immunity*, **2013**, 81, 1245-55	3.7	28
151	In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens. *Journal of Antimicrobial Chemotherapy*, **2013**, 68, 2842-6	5.1	51
150	Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii. *Clinical Infectious Diseases*, **2013**, 57, 543-51	11.6	90
149	Cryptococcus gattii infections: contemporary aspects of epidemiology, clinical manifestations and management of infection. *Future Microbiology*, **2013**, 8, 1613-31	2.9	29
148	Practical identification of eight medically important Trichosporon species by reverse line blot hybridization (RLB) assay and rolling circle amplification (RCA). *Medical Mycology*, **2013**, 51, 300-8	3.9	7
147	Diagnosis of Barmah Forest virus infection by a nested real-time SYBR green RT-PCR assay. *PLoS ONE*, **2013**, 8, e65197	3.7	4
146	One world, one health: beyond the Millennium Development Goals. *Lancet, The*, **2012**, 380, 805-6	40	12
145	Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death. *Clinical Infectious Diseases*, **2012**, 55, 789-98	11.6	136
144	Clinical utility of the cryptococcal antigen lateral flow assay in a diagnostic mycology laboratory. *PLoS ONE*, **2012**, 7, e49541	3.7	91
143	The Crz1/Sp1 transcription factor of Cryptococcus neoformans is activated by calcineurin and regulates cell wall integrity. *PLoS ONE*, **2012**, 7, e51403	3.7	52
142	Identification of novel hybrids between Cryptococcus neoformans var. grubii VNI and Cryptococcus gattii VGII. *Mycopathologia*, **2012**, 173, 337-46	2.9	45
141	Echinocandin antifungal drugs in fungal infections: a comparison. *Drugs*, **2011**, 71, 11-41	12.1	260
140	Doing the right thing for tuberculosis control in the Torres Strait Islands. *Medical Journal of Australia*, **2011**, 195, 512	4	1
139	Skull-base osteomyelitis: fungal vs. bacterial infection. *Clinical Microbiology and Infection*, **2011**, 17, 306-315	5.1	77

138	Nocardia infections of the face and neck. *Current Infectious Disease Reports*, **2011**, 13, 132-40	3.9	12
137	Pneumonia and lung infections due to emerging and unusual fungal pathogens. *Seminars in Respiratory and Critical Care Medicine*, **2011**, 32, 703-16	3.9	24
136	Three-locus identification, genotyping, and antifungal susceptibilities of medically important Trichosporon species from China. *Journal of Clinical Microbiology*, **2011**, 49, 3805-11	9.7	41
135	Miltefosine induces apoptosis-like cell death in yeast via Cox9p in cytochrome c oxidase. *Molecular Pharmacology*, **2011**, 80, 476-85	4.3	42
134	Accurate and practical identification of 20 Fusarium species by seven-locus sequence analysis and reverse line blot hybridization, and an in vitro antifungal susceptibility study. *Journal of Clinical Microbiology*, **2011**, 49, 1890-8	9.7	60
133	Improved identification of Gordonia, Rhodococcus and Tsukamurella species by 5Send 16S rRNA gene sequencing. *Pathology*, **2011**, 43, 58-63	1.6	13
132	Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies. *Leukemia and Lymphoma*, **2011**, 52, 179-93	1.9	12
131	Cryptococcus gattii virulence composite: candidate genes revealed by microarray analysis of high and less virulent Vancouver island outbreak strains. *PLoS ONE*, **2011**, 6, e16076	3.7	50
130	KRE genes are required for beta-1,6-glucan synthesis, maintenance of capsule architecture and cell wall protein anchoring in Cryptococcus neoformans. *Molecular Microbiology*, **2010**, 76, 517-34	4.1	64
129	Epidemiology of paediatric invasive fungal infections and a case-control study of risk factors in acute leukaemia or post stem cell transplant. *British Journal of Haematology*, **2010**, 149, 263-72	4.5	76
128	secA1 gene sequence polymorphisms for species identification of Nocardia species and recognition of intraspecies genetic diversity. *Journal of Clinical Microbiology*, **2010**, 48, 3928-34	9.7	34
127	Reverse line blot hybridization and DNA sequencing studies of the 16S-23S rRNA gene intergenic spacer regions of five emerging pathogenic Nocardia species. *Journal of Medical Microbiology*, **2010** , 59, 548-555	3.2	8
126	Comparison of whole blood, serum, and plasma for early detection of candidemia by multiplex-tandem PCR. *Journal of Clinical Microbiology*, **2010**, 48, 811-6	9.7	76
125	Identification of pathogenic Nocardia species by reverse line blot hybridization targeting the 16S rRNA and 16S-23S rRNA gene spacer regions. *Journal of Clinical Microbiology*, **2010**, 48, 503-11	9.7	19
124	Whole-genome characterization and genotyping of global WU polyomavirus strains. *Journal of Virology*, **2010**, 84, 6229-34	6.6	18
123	Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. *Journal of Antimicrobial Chemotherapy*, **2010**, 65, 1042-51	5.1	129
122	Clinical associations and prevalence of Scedosporium spp. in Australian cystic fibrosis patients: identification of novel risk factors?. *Medical Mycology*, **2010**, 48 Suppl 1, S37-44	3.9	80
121	Detection of occult Scedosporium species in respiratory tract specimens from patients with cystic fibrosis by use of selective media. *Journal of Clinical Microbiology*, **2010**, 48, 314-6	9.7	66

120	Management of invasive candidiasis in the intensive care unit. *Drugs*, **2010**, 70, 823-39	12.1	21
119	In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 3233-40	5.9	8
118	Antifungal therapy in invasive fungal infections. *Current Opinion in Pharmacology*, **2010**, 10, 522-30	5.1	78
117	Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. *Clinical Infectious Diseases*, **2010**, 50, 291-322	11.6	1683
116	Prophylaxis, empirical and preemptive treatment of invasive candidiasis. *Current Opinion in Critical Care*, **2010**, 16, 470-4	3.5	26
115	Pathogenesis of pulmonary Cryptococcus gattii infection: a rat model. *Mycopathologia*, **2010**, 170, 315-30	2.9	30
114	Increasing incidence of candidaemia: long-term epidemiological trends, Queensland, Australia, 1999-2008. *Journal of Hospital Infection*, **2010**, 76, 46-51	6.9	36
113	Recent advances in management of cryptococcal meningitis: commentary. *F1000 Medicine Reports*, **2010**, 2, 82		3
112	Rapid etiological classification of meningitis by NMR spectroscopy based on metabolite profiles and host response. *PLoS ONE*, **2009**, 4, e5328	3.7	27
111	Parainfluenza virus type 3 pneumonia in bone marrow transplant recipients: multiple small nodules in high- resolution lung computed tomography scans provide a radiological clue to diagnosis. *Clinical Infectious Diseases*, **2009**, 48, 905-9	11.6	24
110	Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. *Pediatrics*, **2009**, 123, 1360-8	7.4	142
109	Scedosporium prolificans osteomyelitis in an immunocompetent child treated with a novel agent, hexadecylphospocholine (miltefosine), in combination with terbinafine and voriconazole: a case report. *Clinical Infectious Diseases*, **2009**, 48, 1257-61	11.6	71
108	Rapid detection of ERG11 gene mutations in clinical Candida albicans isolates with reduced susceptibility to fluconazole by rolling circle amplification and DNA sequencing. *BMC Microbiology*, **2009**, 9, 167	4.5	40
107	Synthesis, antifungal, haemolytic and cytotoxic activities of a series of bis(alkylpyridinium)alkanes. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 6329-39	3.4	19
106	Chitotriosidase and gene therapy for fungal infections. *Cellular and Molecular Life Sciences*, **2009**, 66, 1116-25	10.3	31
105	Assessment of clinical risk predictive rules for invasive candidiasis in a prospective multicentre cohort of ICU patients. *Intensive Care Medicine*, **2009**, 35, 2141-5	14.5	39
104	Candidemia following solid organ transplantation in the era of antifungal prophylaxis: the Australian experience. *Transplant Infectious Disease*, **2009**, 11, 122-7	2.7	48
103	Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. *Clinical Microbiology and Infection*, **2009**, 15, 689-93	9.5	85

102	Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management. *Clinical Microbiology and Infection*, **2009**, 15, 662-9	9.5	70
101	Determinants of mortality in non-neutropenic ICU patients with candidaemia. *Critical Care*, **2009**, 13, R115	10.8	68
100	Current status and future perspectives on molecular and serological methods in diagnostic mycology. *Future Microbiology*, **2009**, 4, 1185-222	2.9	44
99	Fungal-derived immune modulating molecules. *Advances in Experimental Medicine and Biology*, **2009**, 666, 108-20	3.6	18
98	Building quality in health--the need for clinical researchers. *Medical Journal of Australia*, **2009**, 190, 627-9	4	3
97	Assignment of reference 5Send 16S rDNA sequences and species-specific sequence polymorphisms improves species identification of Nocardia. *Open Microbiology Journal*, **2009**, 3, 97-105	0.8	21
96	Role and mechanism of phosphatidylinositol-specific phospholipase C in survival and virulence of Cryptococcus neoformans. *Molecular Microbiology*, **2008**, 69, 809-26	4.1	43
95	Multiplex tandem PCR: a novel platform for rapid detection and identification of fungal pathogens from blood culture specimens. *Journal of Clinical Microbiology*, **2008**, 46, 3021-7	9.7	70
94	Association between fertility and molecular sub-type of global isolates of Cryptococcus gattii molecular type VGII. *Medical Mycology*, **2008**, 46, 665-73	3.9	22
93	Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. *Clinical Infectious Diseases*, **2008**, 46, 1813-21	11.6	3744
92	Practical method for detection and identification of Candida, Aspergillus, and Scedosporium spp. by use of rolling-circle amplification. *Journal of Clinical Microbiology*, **2008**, 46, 2423-7	9.7	62
91	Rapid identification and differentiation of Trichophyton species, based on sequence polymorphisms of the ribosomal internal transcribed spacer regions, by rolling-circle amplification. *Journal of Clinical Microbiology*, **2008**, 46, 1192-9	9.7	55
90	Colony multiplex-tandem PCR for rapid, accurate identification of fungal cultures. *Journal of Clinical Microbiology*, **2008**, 46, 4058-60	9.7	23
89	Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. *Critical Care Medicine*, **2008**, 36, 2034-9	1.4	112
88	Molecular typing of Australian Scedosporium isolates showing genetic variability and numerous S. aurantiacum. *Emerging Infectious Diseases*, **2008**, 14, 282-90	10.2	67
87	The role of nuclear magnetic resonance in medical mycology. *Current Fungal Infection Reports*, **2008**, 2, 149-156	1.4	3
86	Clinician response to Candida organisms in the urine of patients attending hospital. *European Journal of Clinical Microbiology and Infectious Diseases*, **2008**, 27, 201-8	5.3	28
85	Role of conserved active site residues in catalysis by phospholipase B1 from Cryptococcus neoformans. *Biochemistry*, **2007**, 46, 10024-32	3.2	6

84	Antifungal agents. *Medical Journal of Australia*, **2007**, 187, 404-9	4	109
83	Synthesis, antifungal and haemolytic activity of a series of bis(pyridinium)alkanes. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 3422-9	3.4	29
82	Synthesis, antifungal and antimicrobial activity of alkylphospholipids. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 5158-65	3.4	27
81	Cryptococcal phospholipase B antigen is not detected in serum of patients infected with Cryptococcus neoformans using a sandwich enzyme-linked immunosorbent assay. *FEMS Yeast Research*, **2007**, 7, 465-70	3.1	1
80	Development and clinical application of a panfungal PCR assay to detect and identify fungal DNA in tissue specimens. *Journal of Clinical Microbiology*, **2007**, 45, 380-5	9.7	230
79	Cell wall-linked cryptococcal phospholipase B1 is a source of secreted enzyme and a determinant of cell wall integrity. *Journal of Biological Chemistry*, **2007**, 282, 37508-14	5.4	63
78	Detection of Fungal Metabolites. *Infectious Disease and Therapy*, **2007**, 121-132		
77	Reverse line blot hybridization assay for identification of medically important fungi from culture and clinical specimens. *Journal of Clinical Microbiology*, **2007**, 45, 2872-80	9.7	45
76	Optimizing therapy for Candida infections. *Seminars in Respiratory and Critical Care Medicine*, **2007**, 28, 678-88	3.9	7
75	Cryptococcal lipid metabolism: phospholipase B1 is implicated in transcellular metabolism of macrophage-derived lipids. *Eukaryotic Cell*, **2007**, 6, 37-47		33
74	In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 2219-22	5.9	33
73	Impact of antifungal resistance in Australia. *Microbiology Australia*, **2007**, 28, 174	0.8	5
72	Simultaneous detection and identification of Candida, Aspergillus, and Cryptococcus species by reverse line blot hybridization. *Journal of Clinical Microbiology*, **2006**, 44, 876-80	9.7	31
71	Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. *Clinical Infectious Diseases*, **2006**, 43, 1031-9	11.6	2
70	Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. *Antimicrobial Agents and Chemotherapy*, **2006**, 50, 414-21	5.9	111
69	Lipid rafts in Cryptococcus neoformans concentrate the virulence determinants phospholipase B1 and Cu/Zn superoxide dismutase. *Eukaryotic Cell*, **2006**, 5, 488-98		86
68	Antifungal effects on metabolite profiles of medically important yeast species measured by nuclear magnetic resonance spectroscopy. *Antimicrobial Agents and Chemotherapy*, **2006**, 50, 4018-26	5.9	16
67	Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. *Journal of Antimicrobial Chemotherapy*, **2006**, 57, 628-38	5.1	126

66	Correlation of antifungal activity with fungal phospholipase inhibition using a series of bisquaternary ammonium salts. *Journal of Medicinal Chemistry*, **2006**, 49, 811-6	8.3	31
65	N-linked glycosylation sites affect secretion of cryptococcal phospholipase B1, irrespective of glycosylphosphatidylinositol anchoring. *Biochimica Et Biophysica Acta - General Subjects*, **2006**, 1760, 1569-79	4	25
64	Active surveillance for candidemia, Australia. *Emerging Infectious Diseases*, **2006**, 12, 1508-16	10.2	135
63	Urgent strategic research into influenza to inform health policy and protect the public. *Medical Journal of Australia*, **2006**, 185, S77-9	4	
62	Application of proton nuclear magnetic resonance spectroscopy to the study of Cryptococcus and cryptococcosis. *FEMS Yeast Research*, **2006**, 6, 558-66	3.1	7
61	Phospholipase B activity enhances adhesion of Cryptococcus neoformans to a human lung epithelial cell line. *Microbes and Infection*, **2006**, 8, 1006-15	9.3	54
60	Role of prospective screening of blood for invasive aspergillosis by polymerase chain reaction in febrile neutropenic recipients of haematopoietic stem cell transplants and patients with acute leukaemia. *British Journal of Haematology*, **2006**, 132, 478-86	4.5	66
59	Complexity of Magnetic Resonance Spectrum Classification **2006**, 241-248		1
58	Detection of antibodies to phospholipase B in patients infected with Cryptococcus neoformans by enzyme-linked immunosorbent assay (ELISA). *Medical Mycology*, **2005**, 43, 335-41	3.9	9
57	Proton nuclear magnetic resonance-based metabonomics for rapid diagnosis of meningitis and ventriculitis. *Clinical Infectious Diseases*, **2005**, 41, 1582-90	11.6	89
56	Diagnosis of cerebral cryptococcoma using a computerized analysis of 1H NMR spectra in an animal model. *Diagnostic Microbiology and Infectious Disease*, **2005**, 52, 101-5	2.9	11
55	Secretion of cryptococcal phospholipase B1 (PLB1) is regulated by a glycosylphosphatidylinositol (GPI) anchor. *Biochemical Journal*, **2005**, 389, 803-12	3.8	61
54	A rapid screening test to distinguish between Candida albicans and Candida dubliniensis using NMR spectroscopy. *FEMS Microbiology Letters*, **2005**, 251, 327-32	2.9	15
53	Identification of Staphylococcus aureus brain abscesses: rat and human studies with 1H MR spectroscopy. *Radiology*, **2005**, 236, 261-70	20.5	27
52	Development of a nested qualitative real-time PCR assay to detect Aspergillus species DNA in clinical specimens. *Journal of Clinical Microbiology*, **2005**, 43, 5366-8	9.7	39
51	Role of extracellular phospholipases and mononuclear phagocytes in dissemination of cryptococcosis in a murine model. *Infection and Immunity*, **2004**, 72, 2229-39	3.7	140
50	In vitro antifungal activities of inhibitors of phospholipases from the fungal pathogen Cryptococcus neoformans. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 1561-9	5.9	48
49	Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. *Internal Medicine Journal*, **2004**, 34, 192-200	1.6	41

48	Antifungal agents for preventing fungal infections in solid organ transplant recipients. *The Cochrane Library*, **2004**, CD004291	5.2	35
47	Cryptococcal phospholipases: a novel lysophospholipase discovered in the pathogenic fungus Cryptococcus gattii. *Biochemical Journal*, **2004**, 384, 377-84	3.8	32
46	PCR-restriction fragment length polymorphism analysis of the phospholipase B (PLB1) gene for subtyping of Cryptococcus neoformans isolates. *Applied and Environmental Microbiology*, **2003**, 69, 2080-6	4.8	52
45	Identification of metabolites of importance in the pathogenesis of pulmonary cryptococcoma using nuclear magnetic resonance spectroscopy. *Microbes and Infection*, **2003**, 5, 285-90	9.3	46
44	Cloning of CnLYSO1, a novel extracellular lysophospholipase of the pathogenic fungus Cryptococcus neoformans. *Gene*, **2003**, 316, 67-78	3.8	11
43	Rapid identification of Candida species by using nuclear magnetic resonance spectroscopy and a statistical classification strategy. *Applied and Environmental Microbiology*, **2003**, 69, 4566-74	4.8	62
42	Strain-dependent effects of environmental signals on the production of extracellular phospholipase by Cryptococcus neoformans. *FEMS Microbiology Letters*, **2002**, 209, 175-81	2.9	12
41	Isolation and characterisation of the phospholipase B gene of Cryptococcus neoformans var. gattii. *FEMS Yeast Research*, **2002**, 2, 551-61	3.1	23
40	Metabolites released by Cryptococcus neoformans var. neoformans and var. gattii differentially affect human neutrophil function. *Microbes and Infection*, **2002**, 4, 1427-38	9.3	49
39	Cerebral nocardiosis characterized by magnetic resonance spectroscopy in vivo. *Clinical Infectious Diseases*, **2002**, 34, 849-52	11.6	14
38	Isolation and characterisation of the phospholipase B gene of Cryptococcus neoformans var. gattii. *FEMS Yeast Research*, **2002**, 2, 551-561	3.1	2
37	Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. *Molecular Microbiology*, **2001**, 39, 166-75	4.1	286
36	Identification of Enterococcus, Streptococcus, and Staphylococcus by multivariate analysis of proton magnetic resonance spectroscopic data from plate cultures. *Journal of Clinical Microbiology*, **2001**, 39, 2916-23	9.7	36
35	Cryptococcomas distinguished from gliomas with MR spectroscopy: an experimental rat and cell culture study. *Radiology*, **2001**, 220, 122-8	20.5	48
34	Purification and characterization of secretory phospholipase B, lysophospholipase and lysophospholipase/transacylase from a virulent strain of the pathogenic fungus Cryptococcus neoformans. *Biochemical Journal*, **2000**, 347, 431-9	3.8	56
33	Purification and characterization of secretory phospholipase B, lysophospholipase and lysophospholipase/transacylase from a virulent strain of the pathogenic fungus Cryptococcus neoformans. *Biochemical Journal*, **2000**, 347, 431-439	3.8	87
32	The origin of 1H NMR-visible triacylglycerol in human neutrophils. Highfatty acid environments result in preferential sequestration of palmitic acid into plasma membrane triacylglycerol. *FEBS Journal*, **2000**, 267, 68-78		19
31	Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. *Clinical Infectious Diseases*, **2000**, 31, 499-508	11.6	373

30	A rapid method for detecting extracellular proteinase activity in Cryptococcus neoformans and a survey of 63 isolates. *Journal of Medical Microbiology*, **2000**, 49, 733-737	3.2	25
29	Biochemical and functional characterisation of secreted phospholipase activities from Cryptococcus neoformans in their naturally occurring state. *Journal of Medical Microbiology*, **1999**, 48, 731-740	3.2	33
28	Heteronuclear NMR studies of metabolites produced by Cryptococcus neoformans in culture media: identification of possible virulence factors. *Magnetic Resonance in Medicine*, **1999**, 42, 442-53	4.4	38
27	Molecular typing of global isolates of Cryptococcus neoformans var. neoformans by polymerase chain reaction fingerprinting and randomly amplified polymorphic DNA-a pilot study to standardize techniques on which to base a detailed epidemiological survey. *Electrophoresis*, **1999**, 20, 1790-9	3.6	199
26	Changes in cellular and plasma membrane phospholipid composition after lipopolysaccharide stimulation of human neutrophils, studied by 31P NMR. *FEBS Journal*, **1997**, 243, 328-35		21
25	Oxidative stress and the mobilisation of arachidonic acid in stimulated human platelets: role of hydroxyl radical. *Prostaglandins*, **1997**, 54, 493-509		13
24	Identification of pathogenic yeasts of the imperfect genus Candida by polymerase chain reaction fingerprinting. *Electrophoresis*, **1997**, 18, 1548-59	3.6	42
23	Identification by random amplification of polymorphic DNA of a common molecular type of Cryptococcus neoformans var. neoformans in patients with AIDS or other immunosuppressive conditions. *Journal of Infectious Diseases*, **1996**, 173, 754-8	7	42
22	Infectious diseases. *Medical Journal of Australia*, **1995**, 162, 104-6	4	2
21	Inhibition of the human platelet cyclooxygenase response by the naturally occurring phenazine derivative, 1-hydroxyphenazine. *Prostaglandins*, **1995**, 50, 301-11		33
20	Inhibition of platelet eicosanoid metabolism by the bacterial phenazine derivative pyocyanin. *Annals of the New York Academy of Sciences*, **1994**, 744, 320-2	6.5	7
19	Circulating polymorphonuclear leukocytes from patients with gram-negative bacteremia are not primed for enhanced production of leukotriene B4 or 5-hydroxyeicosatetraenoic acid. *Journal of Infectious Diseases*, **1994**, 169, 1151-4	7	8
18	Human immunodeficiency virus infection in pregnancy. *Baillière's Clinical Obstetrics and Gynaecology*, **1993**, 7, 45-74		12
17	Pseudomonas aeruginosa bacteraemia. *Medical Journal of Australia*, **1993**, 159, 592-597	4	14
16	GMP-140 (P-selectin) inhibits human neutrophil activation by lipopolysaccharide: analysis by proton magnetic resonance spectroscopy. *Biochemical and Biophysical Research Communications*, **1992**, 183, 1062-9	3.4	15
15	A comparison of hospital and community-acquired infective endocarditis. *American Journal of Cardiology*, **1992**, 70, 1449-52	3	35
14	Comparison of human polymorphonuclear leukocytes from peripheral blood and purulent exudates by high resolution 1H MRS. *Magnetic Resonance in Medicine*, **1991**, 19, 191-8	4.4	28
13	Endocarditis associated with prosthetic cardiac valves. *Medical Journal of Australia*, **1990**, 152, 458, 461-3	4	16

12	Extrapulmonary tuberculosis--a continuing problem in Australia. *Australian and New Zealand Journal of Medicine*, **1987**, 17, 507-11		23
11	Quantitation of sulfidopeptide leukotrienes by reversed-phase high-performance liquid chromatography. *Biomedical Applications*, **1985**, 343, 213-8		16
10	A prospective study of adverse reactions associated with vancomycin therapy. *Journal of Antimicrobial Chemotherapy*, **1985**, 16, 235-41	5.1	165
9	Production of metabolic products of arachidonic acid during cell-cell interactions. *Journal of Allergy and Clinical Immunology*, **1984**, 74, 338-42	11.5	17
8	Host defences in the upper genital tract of the female: studies in a murine system. *The Australian Journal of Experimental Biology and Medical Science*, **1983**, 61 (Pt 3), 287-99		1
7	Phenytoin sensitivity in a case of phenytoin-associated Hodgkin's disease. *Australian and New Zealand Journal of Medicine*, **1975**, 5, 144-7		5
6	Signaling Cascades and Enzymes as Cryptococcus Virulence Factors217-234		1
5	Clinical Perspectives on Cryptococcus neoformans and Cryptococcus gattii: Implications for Diagnosis and Management595-606		13
4	Aspergillus and Penicillium2030-2056		7
3	Metatranscriptomics as a tool to identify fungal species and subspecies in mixed communities		1
2	Revealing COVID-19 Transmission by SARS-CoV-2 Genome Sequencing and Agent Based Modelling		26
1	CCMetagen: comprehensive and accurate identification of eukaryotes and prokaryotes in metagenomic data		2